Bionano Genomics, Inc. (BNGO)
$1.14
Rating:
Recommendation:
-
| Symbol | BNGO |
|---|---|
| Price | $1.14 |
| Beta | 2.317 |
| Volume Avg. | 6.55M |
| Market Cap | 349.112M |
| Shares () | - |
| 52 Week Range | 1.06-4.35 |
| 1y Target Est | - |
| DCF Unlevered | BNGO DCF -> | |
|---|---|---|
| DCF Levered | BNGO LDCF -> | |
| ROE | -47.06% | Strong Sell |
| ROA | -43.12% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 23.30% | Neutral |
| P/E | -2.71 | Sell |
| P/B | 1.32 | Strong Buy |
Latest BNGO news
About
Download (Excel)Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.